Retatrutide in Court, Compound GLP-1 Under Fire

This week on On The Pen, The Weekly Dose Podcast, retatrutide heads into a major federal court fight as the Department of Justice gives FDA fresh legal ammunition just days before oral argument.

At the same time, FDA is escalating its scrutiny of mass GLP-1 compounding, with a warning letter to Empower Pharmacy that could have major implications for semaglutide, tirzepatide, telehealth prescribing, and patient access.

We also break down Viking Therapeutics’ new VK2735 maintenance data, including early weight-loss numbers that are starting to draw retatrutide comparisons and the possibility of every-other-week or even monthly maintenance dosing.

Plus, Roche’s enicepatide, formerly CT-388, just posted a 2.65 percentage-point A1C reduction and 15.5% weight loss in people with type 2 diabetes and obesity, raising new questions about how competitive the next generation of GLP-1/GIP drugs may become.

This episode is about more than one drug. It is about where obesity medicine is heading, who gets access, how regulators are drawing the lines, and why the next few years may look very different from the market we know today.

Https://www.onthepen.com

Https://www.otplinks.com

Denne episoden er hentet fra en åpen RSS-feed og er ikke publisert av Podme. Den kan derfor inneholde annonser.

Episoder(217)

NEW FDA ZEPBOUND WARNING!

VOTE FOR DAVE: https://tophost.org/2026/david-knappThe FDA just issued a NEW eye warning for EVERY GLP-1 medication, including Ozempic, Wegovy, Mounjaro, and Zepbound. But how worried should patients ...

10 Nov 28min

Novo's Next Weight Loss Pill Isn't a GLP-1, And That's HUGE

What if the next big breakthrough in obesity medicine isn't a GLP-1 at all?Novo Nordisk is developing an experimental oral weight-loss medication called LX9851, an ACSL5 inhibitor that targets an enti...

4 Nov 23min

Retatrutide Phase 3 Results: What You Need to Know

Retatrutide’s New Phase 3 Data, CagriSema in Menopause, and the Growing GLP‑1 Access CrisisHost Dave Knapp recaps major obesity-drug updates, focusing on Eli Lilly’s triple agonist retatrutide and Nov...

27 Okt 31min

GLP-1 Recall Update: Why You Need to Check Your Vials

Specific lots of compounded tirzepatide have been recalled over sterility concerns, another pharmacy recently recalled compounded semaglutide after particulate matter was identified, patients have rep...

20 Okt 27min

Eli Lilly vs. The Grey Market: The Future of Peptide Medicine

Eli Lilly’s fight over retatrutide may be about much more than one obesity drug.I’ve been covering retatrutide since early 2023, and since late 2024 I’ve been closely following the legal fight over wh...

14 Okt 25min

Ozempic & Zepbound Are Changing America in Ways Nobody Expected

Zepbound isn’t just changing people’s weight. GLP-1 medications are beginning to change America itself.Restaurants are rethinking what they serve. Grocery baskets are changing. Food companies are payi...

7 Okt 24min

They TRIPLED Wegovy Dose, Does it Beat Zepbound?

This week on On The Pen, The Weekly Dose, we break down one of the biggest weeks in obesity medicine coming out of EASD 2026.Eli Lilly says Zepbound may still outperform Wegovy 7.2 mg, even after Novo...

1 Okt 30min